Cited by 190Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study

Open access
Huang, Daniel Q., Wilson, Laura A., Behling, Cynthia, Kleiner, David E., Kowdley, Kris V., Dasarathy, Srinivasan, Amangurbanova, Maral, Terrault, Norah A. +81 more·2023·Gastroenterology

Abstract

Background & aims There are limited data regarding fibrosis progression in biopsy-proven nonalcoholic fatty liver disease (NAFLD) in people with type 2 diabetes mellitus (T2DM) compared with people without T2DM. We assessed the time to fibrosis progression in people with T2DM compared with people without T2DM in a large, multicenter, study of people with NAFLD who had paired liver biopsies.Methods This study included 447 adult participants (64% were female) with NAFLD who had paired liver biopsies more than 1 year apart. Liver histology was systematically assessed by a central pathology committee blinded to clinical data. The primary outcome was the cumulative incidence of a ≥1-stage increase in fibrosis in participants with T2DM compared with participants without T2DM.Results The mean (SD) age and body mass index (calculated as weight in kilograms divided by the square of the height in meters) were 50.9 (11.5) years and 34.7 (6.3), respectively. The median time between biopsies was 3.3 years (interquartile range, 1.8-6.1 years). Participants with T2DM had a significantly higher cumulative incidence of fibrosis progression at 4 years (24% vs 20%), 8 years (60% vs 50%), and 12 years (93% vs 76%) (P = .005). Using a multivariable Cox proportional hazards model adjusted for multiple confounders, T2DM remained an independent predictor of fibrosis progression (adjusted hazard ratio, 1.69; 95% CI, 1.17-2.43; P = .005). The cumulative incidence of fibrosis regression by ≥1 stage was similar in participants with T2DM compared with participants without T2DM (P = .24).Conclusions In this large, multicenter cohort study of well-characterized participants with NAFLD and paired liver biopsies, we found that fibrosis progressed faster in participants with T2DM compared with participants without T2DM. These data have important implications for clinical practice and trial design.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2023.04.025

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a study of 447 adults with MASLD and paired liver biopsies more than 1 year apart, individuals with T2D had a significantly higher cumulative incidence of fibrosis progression at 4 years (24% vs 20%), 8 years (60% vs 50%), and 12 years (93% vs 76%), with an adjusted HR of 1.69 (95% CI 1.17-2.43).

    “in a study on 447 adult participants with MASLD and paired liver biopsies > 1 year apart, individuals with T2D had a signi fi cantly higher cumulative incidence of fi brosis progression at 4 years (24% vs. 20%), 8 years (60% vs. 50%), and 12 years (93% vs. 76%) ( p < 0.005), with an adjusted HR of 1.69 (95% con fi dence interval [CI], 1.17 -2.43; p < 0.005) on multivariate analysis.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 13

  1. Daniel Q. Huang, MBBS, FRCP (Conceptualization: Supporting; Formal analysis: Supporting; Investigation: Lead; Methodology: Equal; Writing - original draft: Lead; Writing -review & editing: Lead).
  2. Cynthia Behling, MD (Data curation: Supporting; Writing -review & editing: Supporting).
  3. David E. Kleiner, MD (Data curation: Supporting; Writing -review & editing: Supporting).
  4. Kris V. Kowdley, MD (Writing -review & editing: Supporting).
  5. Srinivasan Dasarathy, MD (Writing -review & editing: Supporting).
  6. Maral Amangurbanova, MD (Writing -review & editing: Supporting).
  7. Norah A. Terrault, MD (Writing -review & editing: Supporting).
  8. Anna Mae Diehl, MD (Writing -review & editing: Supporting).
  9. Naga Chalasani, MD (Writing -review & editing: Supporting).
  10. Brent A. Neuschwander-Tetri, MD (Writing -review & editing: Supporting).
  11. Arun J. Sanyal, MD (Writing -review & editing: Supporting).
  12. James Tonascia, PhD (Methodology: Supporting; Writing -review & editing: Supporting).
  13. Rohit Loomba, MD, MHSc (Conceptualization: Lead; Formal analysis: Supporting; Funding acquisition: Lead; Investigation: Equal; Methodology: Lead; Project administration: Lead; Resources: Lead; Supervision: Lead; Visualization: Lead; Writing -review & editing: Supporting).

Cited by

Sorted by citations

Authors
Huang, D. Q., Wilson, L. A., Behling, C., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Amangurbanova, M., Terrault, N. A., Diehl, A. M., Chalasani, N., Neuschwander-Tetri, B. A., Sanyal, A. J., Tonascia, J., Allende, D., Bellar, A., Dasarathy, J., Dasarathy, S., Welch, N., Yerrapothu, R., Bashir, M., Diehl, A. M., Guy, C., Kopping, M., Piercy, D., Suzuki, A., Tawadrou, N., Chalasani, N., Cruz, M., Cummings, O. W., Garrison, L., Gawrieh, S., Samala, N., Vuppalanchi, R., Carpenter, D., Cattoor, T., Freebersyser, J., Neuschwander-Tetri, B. A., Angkanaworakul, P., Berihun, A., Buysse, A., Dorrian, T., Gulati, B., Kowdley, K. V., Liu, K., Misic, S., Sohal, A., Vuong, J., Ajmera, V., Behling, C., Loomba, R., Madamba, E., Middleton, M. S., Richards, L., Singh, S., Sirlin, C., Gill, R., Hameed, B., Awe, R., Olvera, D., Terrault, N., Yuan, L., Yeh, M., Albhaisi, S., Asgharpour, A., Boyett, S., Contos, M. J., Luketic, V. A. C., Sanyal, A. J., Schlosser, J., Siddiqui, M. S., Kleiner, D. E., Adamo, P., Belt, P., Clark, J. M., DeSanto, J. M., Meinert, J., Miriel, L., Mitchell, E. P., Shade, C., Smith, J., Smith, M., Sternberg, A., Tonascia, J., Van Natta, M. L., Wagoner, A., Wilson, L. A., Woreta, T., Yates, K. P., & Loomba, R.
Affiliations
  • National University of Singapore (SG)
  • University of California San Diego (US)
  • Cleveland Clinic (US)
  • Duke Medical Center (US)
  • Indiana University School of Medicine (US)
  • Saint Louis University (US)
  • Liver Institute Northwest (US)
  • University of California, San Francisco (US)
  • University of Southern California (US)
  • University of Washington Medical Center (US)
  • Virginia Commonwealth University (US)
  • Johns Hopkins University (US)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2023-08
Volume
165
Issue
2
Pages
463-472.e5
ISSN
0016-5085 (ISSN-L)
OpenAlex
W4367397089
Cited by
190
References
40
Citations by year
2026: 50 · 2025: 64 · 2024: 55 · 2023: 20
FWCI
37.59
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Center for Advancing Translational Sciences (U01AA029019, UL1TR000436, UL1TR000439, UL1TR002649, UL1TR000004, UL1TR000100, UL1TR000448, UL1TR000423, UL1TR000006)
  • Takeda Pharmaceuticals North America
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061732, U01DK061737, U01DK061738, U01DK061713, U24DK061730, R01DK121378, R01DK106419, P30DK120515, U01DK061718, R01DK124318, U01DK061734, U01DK130190, U01DK061728)
  • National Institutes of Health
  • Ministry of Health -Singapore
  • National Institute on Alcohol Abuse and Alcoholism
  • National Medical Research Council (MOH-000595-01)
  • National Cancer Institute (NCT00063622)
  • National Heart, Lung, and Blood Institute (P01HL147835)
  • National Institute of Environmental Health Sciences (5P42ES010337, 5UL1TR001442)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
non-alcoholic fatty liver disease, type 2 diabetes, liver fibrosis progression, fibrosis regression, liver histopathology, cumulative incidence, diabetes as risk factor
MeSH terms
Adult, Biopsy, Diabetes Mellitus, Type 2, Female, Humans, Liver Cirrhosis, Male, Cohort Studies, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review